Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center), Ruifang Sun(Union Hospital), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Benjamin M. Parsons(Gundersen Health System), Maurilio Ponzoni(San Raffaele University of Rome), Eric D. Hsi(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Attilio Orazi(Texas Tech University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Kristy L. Richards(University of North Carolina at Chapel Hill), April Chiu(Mayo Clinic), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Youli Zu(Methodist Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Timothy J. McDonnell(Health Service Executive), Jooryung Huh(Asan Medical Center), Xiaoxiao Wang(Soochow University), Yong Li(Baylor College of Medicine), Li Zhang(Chongqing Emergency Medical Center), Lihui Yin(The University of Texas MD Anderson Cancer Center), Xiaoying Zhao(Handan College), Yi Xia(The University of Texas MD Anderson Cancer Center), Andrés JM Ferreri, William W.L. Choi(Chinese University of Hong Kong), Meifeng Tu(Peking University), L. Jeffrey Medeiros(Delaware Division of Libraries), Bouthaina S. Dabaja(The University of Texas MD Anderson Cancer Center), Jane N. Winter(Northwestern University)
Modern Pathology
November 6, 2015
Cited by 54


Related Papers